ArticleNature communications2018
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
218citing papers in PubMed, 1 pooled it
23.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 1 synthesis or guideline pooled it, 364 citations in OpenAlex.
- Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma.Frontiers in oncology · 2021Pooled it
- An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas.The oncologist · 2020Trial
- Molecular, histopathological, and clinical risk factors for overall metastatic disease and brain metastases in surgically resected stage I-III lung cancer.Clinical & experimental metastasis · 2026Article
- Brief Report: Proposed Clinical Trial Guidelines Based on Clinicopathologic Heterogeneity of Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
- Divergent c-MYC Expression Patterns in NET and NEC: Insights from a Multicentre Cohort of 1380 Neuroendocrine Neoplasms.Endocrine pathology · 2026Article
- Adjuvant chemotherapy and survival after resection for pulmonary large-cell neuroendocrine carcinoma: a dual-center time-dependent analysis.Translational lung cancer research · 2026Article
- A targetable dependency on nonsense-mediated decay for cellular homeostasis and immune control in small cell lung cancer.Molecular cancer · 2026Article
- De Novo Actionable Genomic Alterations in High-Grade Pulmonary Neuroendocrine Carcinomas: Therapeutic Implications of Targeted Treatment.Medical sciences (Basel, Switzerland) · 2026Article
- Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy.Science advances · 2026Article
- Transcriptional evidence of neuroendocrine cell plasticity beyond histological boundaries in lung neuroendocrine neoplasms: an in-silico analysis suggesting a progression model.Journal of experimental & clinical cancer research : CR · 2026Article
- Clinical practice review of systemic treatment in large cell neuroendocrine carcinoma.Translational lung cancer research · 2026Review
- Deep learning based histomorphological phenotyping and prognostic stratification for combined SCLC and LCNEC.NPJ digital medicine · 2026Article
- The role of HNF4α in adenocarcinoma.Biochemical Society transactions · 2026Review
- Identification of Actionable Gene Variants in Pulmonary Large-Cell Neuroendocrine Carcinoma: A Real-World Analysis of a Polish Cohort.International journal of molecular sciences · 2026Article
- Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities.Genome medicine · 2026Article
- Review
- Integrative multi-omics profiling deciphers tumor microenvironment heterogeneity and immunotherapy vulnerabilities in lung neuroendocrine carcinomas.Journal of advanced research · 2026Article
- Altered DNA Methyltransferase Expression in Pulmonary Large-Cell Neuroendocrine Carcinoma: Pilot Experimental Data Targeted DNMT1, DNMT3A, and DNMT3B.Cancer reports (Hoboken, N.J.) · 2026Article
- Case report: ALK inhibitor-induced transformation of ALK fusion-positive lung adenocarcinoma to large cell neuroendocrine carcinoma.NPJ precision oncology · 2026Article
158 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
62 authors at 20 institutions in 7 countries.
Julie GeorgeDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany. jgeorge@uni-koeln.de.
Vonn WalterUNC Lineberger Comprehensive Cancer Center School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7295, USA.
Martin PeiferDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.ORCID http://orcid.org/0000-0002-5243-5503
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine and Department of Bioengineering and Moores Cancer Center, University of California, La Jolla, San Diego, CA, 92093, USA.ORCID http://orcid.org/0000-0003-3596-4515
Danila SeidelDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.
Frauke LeendersDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.
Lukas MaasDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.
Christian MüllerDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.
Ilona DahmenDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.
Tiffany M DelhommeGenetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), Lyon, 69008, France.
Maude ArdinMolecular Mechanisms and Biomarkers Group, Section of Mechanisms of Carcinogenesis, International Agency for Research on Cancer (IARC-WHO), 69008, Lyon, France.
Noemie LeblayGenetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), Lyon, 69008, France.
Graham ByrnesSection of Environment and Radiation, International Agency for Research on Cancer (IARC-WHO), 69008, Lyon, France.
Ruping SunComputational Molecular Biology Group, Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany.ORCID http://orcid.org/0000-0003-3702-9483
Aurélien De ReyniesProgramme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, 14 rue Corvisart, Paris, 75013, France.
Anne McLeer-FlorinCHU Grenoble Alpes, UGA/INSERM U1209/CNRS, Grenoble, France.
Graziella BoscoDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.
Florian MalchersDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.
Roopika MenonNEO New Oncology GmbH, 51105, Cologne, Germany.
Janine AltmüllerCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931, Cologne, Germany.
Christian BeckerCologne Center for Genomics (CCG), University of Cologne, 50931, Cologne, Germany.
Peter NürnbergCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931, Cologne, Germany.
Viktor AchterComputing Center, University of Cologne, 50931, Cologne, Germany.
Ulrich LangComputing Center, University of Cologne, 50931, Cologne, Germany.
Peter M SchneiderInstitute of Legal Medicine, University Hospital Cologne, 50823, Cologne, Germany.ORCID http://orcid.org/0000-0003-0744-2349
Magdalena BogusInstitute of Legal Medicine, University Hospital Cologne, 50823, Cologne, Germany.
Matthew G SolowayUNC Lineberger Comprehensive Cancer Center School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7295, USA.
Matthew D WilkersonDepartment of Genetics, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, NC, 27599-7295, USA.
Yupeng CunDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.ORCID http://orcid.org/0000-0002-4241-8099
James D McKayGenetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), Lyon, 69008, France.
Denis Moro-SibilotCHUGA Grenoble, INSERM U 1209, University Grenoble Alpes, Institute of Advanced Biosciences (IAB), 38043, CS10217, Grenoble, France.
Christian G BrambillaCHUGA Grenoble, INSERM U 1209, University Grenoble Alpes, Institute of Advanced Biosciences (IAB), 38043, CS10217, Grenoble, France.
Sylvie LantuejoulDepartment of Pathology, CHUGA, INSERM U 1209, University of Grenobles Alpes, Institute of Advanced Biosciences (IAB), 38043, CS10217, Grenoble, France.
Nicolas LemaitreDepartment of Pathology, CHUGA, INSERM U 1209, University of Grenobles Alpes, Institute of Advanced Biosciences (IAB), 38043, CS10217, Grenoble, France.
Alex SoltermannInstitute of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland.
Walter WederDepartment of Thoracic Surgery, University Hospital Zurich, 8091, Zurich, Switzerland.
Verena TischlerInstitute of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland.
Odd Terje BrustugunInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0424, Oslo, Norway.
Marius Lund-IversenDepartment of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310, Oslo, Norway.
Åslaug HellandDepartment of Thoracic Surgery, University Hospital Zurich, 8091, Zurich, Switzerland.
Steinar SolbergDepartment of Thoracic Surgery, Rikshospitalet, Oslo University Hospital, N-0027, Oslo, Norway.
Sascha AnsénDepartment of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, 50937, Cologne, Germany.
Gavin WrightDepartment of Surgery, St. Vincent's Hospital, Peter MacCallum Cancer Centre, 3065, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-7000-9305
Benjamin SolomonDepartment of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, 3065, Melbourne, Victoria, Australia.
Luca RozTumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS-Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy.
Ugo PastorinoThoracic Surgery Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, 20133, Milan, Italy.
Iver PetersenInstitute of Pathology, Jena University Hospital, Friedrich-Schiller-University, 07743, Jena, Germany.
Joachim H ClementDepartment of Internal Medicine II, Jena University Hospital, Friedrich-Schiller-University, 07743, Jena, Germany.
Jörg SängerInstitute for Pathology Bad Berka, 99438, Bad Berka, Germany.
Jürgen WolfDepartment of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, 50937, Cologne, Germany.
Martin VingronComputational Molecular Biology Group, Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany.ORCID http://orcid.org/0000-0002-1765-4241
Thomas ZanderGastrointestinal Cancer Group Cologne, Center of Integrated Oncology Cologne-Bonn, Department I for Internal Medicine, University Hospital of Cologne, 50823, Cologne, Germany.
Sven PernerPathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Center for Medicine and Biosciences, 23538 Luebeck and 23845 Borstel, Borstel, Germany.
William D TravisDepartment of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.
Stefan A HaasComputational Molecular Biology Group, Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany.
Magali OlivierMolecular Mechanisms and Biomarkers Group, Section of Mechanisms of Carcinogenesis, International Agency for Research on Cancer (IARC-WHO), 69008, Lyon, France.
Matthieu FollGenetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), Lyon, 69008, France.
Reinhard BüttnerDepartment of Pathology, University Hospital Cologne, 50937, Cologne, Germany.
David Neil HayesUNC Lineberger Comprehensive Cancer Center School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7295, USA.
Elisabeth BrambillaDepartment of Pathology, CHUGA, INSERM U 1209, University of Grenobles Alpes, Institute of Advanced Biosciences (IAB), 38043, CS10217, Grenoble, France. EBrambilla@chu-grenoble.fr.
Lynnette Fernandez-CuestaDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany.
Roman K ThomasDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, 50931, Germany. roman.thomas@uni-koeln.de.
University of Cologne · DECentre international de recherche sur le cancer · FRUniversity Hospital Cologne · DEInserm · FRUniversity of North Carolina at Chapel Hill · USMax Planck Institute for Molecular Genetics · DEOslo University Hospital · NOUniversity Hospital of Zurich · CHFondazione IRCCS Istituto Nazionale dei Tumori · ITJena University Hospital · DEPeter MacCallum Cancer Centre · AUCentre National de la Recherche Scientifique · FRGerman Cancer Research Center · DELa Ligue Contre le Cancer · FRMemorial Sloan Kettering Cancer Center · USResearch Center Borstel - Leibniz Lung Center · DETH Köln - University of Applied Sciences · DEUniversity of California San Diego · USUniversity of Oslo · NOZentralklinik Bad Berka · DE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNetwork Group Integrated Translational Science Centers ApplicationU10CA181009 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, PEROU, CHARLES M · 2014 to 2018
$3.4MNCI NIH HHS P30 CA008748NCI NIH HHS U10 CA181009World Health Organization 001
Abstract
Pulmonary large-cell neuroendocrine carcinomas (LCNECs) have similarities with other lung cancers, but their precise relationship has remained unclear. Here we perform a comprehensive genomic (n = 60) and transcriptomic (n = 69) analysis of 75 LCNECs and identify two molecular subgroups: "type I LCNECs" with bi-allelic TP53 and STK11/KEAP1 alterations (37%), and "type II LCNECs" enriched for bi-allelic inactivation of TP53 and RB1 (42%). Despite sharing genomic alterations with adenocarcinomas and squamous cell carcinomas, no transcriptional relationship was found; instead LCNECs form distinct transcriptional subgroups with closest similarity to SCLC. While type I LCNECs and SCLCs exhibit a neuroendocrine profile with ASCL1
Indexed as
Carcinoma, NeuroendocrineCarcinoma, Non-Small-Cell LungDNA Mutational AnalysisGenomicsHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryIn Situ Hybridization, FluorescenceIn Vitro TechniquesLung NeoplasmsNeuroendocrine TumorsSmall Cell Lung Carcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.